Dokumendiregister | Terviseamet |
Viit | 7-8/25/706-1 |
Registreeritud | 27.01.2025 |
Sünkroonitud | 28.01.2025 |
Liik | Sissetulev dokument |
Funktsioon | 7 Kriisireguleerimine |
Sari | 7-8 Kirjavahetus kriisireguleerimist puudutavates küsimustes |
Toimik | 7-8/2025 |
Juurdepääsupiirang | Avalik |
Juurdepääsupiirang | |
Adressaat | Politsei- ja Piirivalveamet |
Saabumis/saatmisviis | Politsei- ja Piirivalveamet |
Vastutaja | Ragnar Vaiknemets (TA, Peadirektori asetäitja (3) vastutusvaldkond) |
Originaal | Ava uues aknas |
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. |
Tere,
Saadan Novo Nordiski poolt välja töötatud infopaketi Ozempicu (ja seotud toodete) kohta teadmiseks ja vajadusel ametite sees edasi jagamiseks,
Kui Eestil on antud teemas mingit infot või juhtumeid, palutakse seda jagada ka Interpoliga-
Tervitan
Anneli Kolgo-Makki
Ametiabi grupp
Rahvusvahelise ametiabi keskus
Rahvusvahelise operatiivinfo büroo
Piirivalveosakond
Politsei- ja Piirivalveamet
Tööstuse 52, 10416 Tallinn
Tel 612 3797 (73797)
*** AMETIALASEKS KASUTAMISEKS *** Selles e-kirjas sisalduv teave (kaasa arvatud manused) on mõeldud ametialaseks kasutamiseks ning seda võivad kasutada vaid e-kirja adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt väljendatud loata edasi saata ega mistahes viisil kõrvalistele isikutele avaldada. Juhul, kui Te olete saanud käesoleva e-kirja eksituse tõttu, teavitage sellest koheselt saatjat ning kustutage e-kiri oma arvutist. This e-mail and any attachments may contain confidential and privileged information. If you are not the intended recipient, please notify the sender immediately by return e-mail, delete this e-mail and destroy any copies. Any dissemination or use of this information by a person other than the intended recipient is unauthorized and may be illegal
From: NG Perry <[email protected]>
Sent: Monday, January 27, 2025 7:17 AM
To: NCB Tallinn <[email protected]>
Cc: OEC-CNET-IGGH <[email protected]>
Subject: Intelligence package on counterfeit Ozempic and related products (For Estonia)
FROM : IPSG
OEC/CNET/IGGH
Your ref: New
Our ref: 2025/117/OEC/CNET/IGGH/PHPC/PNG
Dear NCB colleagues,
We hope our email finds you well.
In the framework of Operation Pangea XVII and following up from our alerts regarding the increasing trends of counterfeit Ozempic related products globally, we would like to provide you with the attached intelligence package (for Estonia) prepared by the brand owner (Novo Nordisk).
We kindly request that you disseminate to the relevant national agency for their monitoring of the situation.
Please do not hesitate to contact us should you have any further intelligence or cases for INTERPOL to support your investigations.
We look forward to your acknowledgement of this message.
Thank you.
Best regards,
……………………………………………
Perry NG
Criminal Intelligence Officer
Criminal Networks
Public Health and Pharmaceutical Crime
INTERPOL Global Complex for Innovation
18 Napier Road, Singapore 258510
Office Phone: +65 6550 3641
Attention: Our products have gained world-wide attention mainly due to weight-loss effects.
Counterfeit: This has lead to a surge of counterfeit products.
What?
Novo Nordisk is a Danish pharmaceutical company specialized in diabetes and
obesity.
Who is Novo Nordisk?
Background
Prescription Drugs ONLY
Cold Chain (2-8 °C)
Patient safety: Failure to comply with label or instruction may cause safety concerns
Dangerous: Counterfeit may cause patient harm
Low quality Failure to observe cold-chain or storage requirements may cause patient harm
Why?
Ozempic® is approved for treatment of type 2 diabetes.
It is injected once weekly.
Norditropin® is a growth hormone approved for
treatment of growth disorders.
Rybelsus is approved for treatment of type 2 diabetes.
It is taken as a tablet daily.
Wegovy® is approved for treatment of obesity. It is
injected once weekly.
At-risk Products
How to detect counterfeit products? Keep these 3 things in mind:
Illicit Sales Channels
Quality &
Origin
Contact Novo Nordisk
1. The Sales channel The counterfeits are found on both physical and online channels • Our products should only be sold in
legitimate channels.
2. Quality & Origin The products require professional distribution and cold chain networks. • Our products are only produced by certain
factories
3. Contact Novo Nordisk If you have suspicions that counterfeit products are making it to your market, please contact Novo Nordisk.
WHAT is it about? Sales of semaglutide is increasing online and offline.
• Online sales: E-commerce platforms, social media (influencers and illegal sellers) and fake websites
• Offline sales: Pharmacies, gyms clubs
1. The sales channels
Illicit Sales channels
Sales Sources
HOW to manage it? For online sales: • Be aware on social media (TikTok, X (Ex-Twitter), Facebook…) • The fake advertisements redirect to fraudulent websites • Notify us and will take care of the website shutdown For offline sales: • In any case of suspicious NN product sales, contact us.
Example Ozempic Packaging labelled ”Bayer” found in a gym
Example Ozempic sells online
ORIGIN of the product Our products are only manufactured at the listed sites here
• It is counterfeit if products are claimed manufactured elsewhere
Trends: • Counterfeit Rybelsus from China • Counterfeit Ozempic from Turkey (on the rise)
2. Quality & Origin
Quality &
Origin
Check product quality!
VERIFICATION of packaging • Check the dates • Check the batch number below the dates • If the batch number is in this list, be suspicious • Check the general packaging (Novo Nordisk logo, spelling
errors, quality of openings…)
Example Fake batch number
Example Incorrect packaging (wrong logo and design)
Example Spelling errors on packaging
Suspicion? If you have suspicions that counterfeit products are making it to your market, please contact the people below or directly Global Security
3. Contact Novo Nordisk
Contact Novo Nordisk
We’re available 24/7!
CONTACT PERSONS:
Anne DEVAUD Head Global Product Security (Global) [email protected]
Jim HENDERSON Director Risk Management (US) [email protected]
Benedict CHEN Regional Security Advisor (APAC) [email protected]
Stephen YARDLEY Regional Security Advisor (EMEA) [email protected]
Renata PEREIRA Regional Security Advisor (LATAM) [email protected]
Maria Magdalena Korzycka Global Product Security Coordinator [email protected]
88
Our Production Facilities
Brazil Monte Claros Company: Novo Nordisk Brazil
USA Clayton, Durham, New Hampshire Company: Novo Nordisk Inc. / Novo Nordisk USA (Clayt.)
Japan Koriyama Company: Novo Nordisk Japan
Denmark Bagsværd, Kalundborg, Hillerød, Gentofte, Værløse, Måløv Company: Novo Nordisk Denmark / Novo Nordisk A/S
France Chartres Company: NN France Production
China Tianjin Company: Novo Nordisk China
Our at-risk products are all manufactured from one of these sites. • Any product packaging claiming to be
manufactured elsewhere is counterfeit
If you see a company that doesn’t belong to the one the side, you can’t trust it and you should directly report the shipment
Iran Tehran Company: NN Pars (PSJ)
Algeria Blida, Tizi Ouzou Company: Aldaph SPA
Russia Kaluga Company: Novo Nordisk Russia
All NN products entering ESTONIA come via these importers and at these ports of entry:
Importers and distributors: Producers:
• Novo Nordisk A/S
• NN France Production
• Novo Nordisk Brazil
Distributors:
• Magnum Medical OU
• TAMRO EESTI OU
• BALTFARMA OU
Port of entry: • Magnum Medical LTd.
If you see a company that doesn’t belong to these lists, you can’t trust it and you need to directly report the shipment
Products imported, distributed or with a point of entry elsewhere, are counterfeit or diverted
Main Batch Numbers at risk
Batch Number
If you notice a batch number from this list on a shipment, please be vigilant!
• Batch numbers are written on the back of the packaging, below the dates • They are important numbers for us to track our products and their origin
Currently, we observe the following batch number at risk: Batch do not exist with
NN Product
NS6GG22 Rybelsus®
FT4A281 Ozempic®
NDC7139 Norditropin®
MC74746 Norditropin®
MG5B070 Ozempic®
JS7A925 Ozempic®
NPSG234 Ozempic®
9F808A Norditropin®
Frequently used Batch numbers
Product
MP5B060 Ozempic®
NP5E775 Ozempic®
NS6JT27 Rybelsus®
NO6F617 Wegovy®
• For Ozempic MP5B060, if its 1 mg it is a counterfeit. • For Ozempic NP5E775, batch number does not exist for Ozempic but
exist for Saxenda and sold in Argentina • For Rybelsus NS6JT27, batch number does not exist for Rybelsus but
exist for NovoEight intended to be sold in Colombia
Norditropin® SimpleXx® no more in production worldwide, but still counterfeited
CF Batch numbers: FC83012, NDC7139, MC74746, 9F808A Seen recently in Turkey and Greece Abused by bodybuilders
Counterfeit Rybelsus example • Rybelsus ranks as the second-most
counterfeited Novo Nordisk product • Examine the packaging for spelling
mistakes • The provided images highlight the
spelling discrepancies identified
Genuine Counterfeit
How to differentiate: • Dose Selector extends up to 80
on counterfeit • Label on the pen and carton:
poor quality and not adhering well to the pen
• Counterfeit needles: ALVITA
Modus operandi: • Counterfeiters utilized Apidra SoloStar pens that resemble those of Saxenda. The pens are Sanofi's product, designed for
administering rapid-acting insulin. • They substituted the original Apidra labels with counterfeit Saxenda labels
• They distributed Alvita needles with the pens, in place of Novo Nordisk’s own
Genuine Saxenda® pen
Fake Saxenda pen: • Fake label of poor
quality • Not adhering well
to the pen
Counterfeit Saxenda example
New Modus operandi - NN genuine rapid insulin pen relabeled as Ozempic
Counterfeit
Genuine
Genuine Fiasp® pen
How to differentiate: • Counterfeiters are using
NN rapid insulin pens and relabelling them as Ozempic
• The Ozempic® pen is light blue with a gray injection button, while Fiasp® insulin pens are dark blue with an orange button
Genuine Counterfeit
Counterfeit Ozempic example
How to differentiate: • Dose Selector extends up to 80
on counterfeit • Label on the pen and carton:
poor quality and not adhering well to the pen
• Counterfeit needles: ALVITA
Fake Ozempic pen: • Fake label of poor quality
• Not adhering well to the pen
Modus operandi: • Counterfeiters utilized Apidra SoloStar pens (1) that resemble those of Ozempic (2). The pens are Sanofi's product, designed for
administering rapid-acting insulin. • They substituted the original Apidra labels with counterfeit Ozempic labels (3) • They distributed Alvita needles (4) with the pens, in place of Novo Nordisk’s own
1 2
3 4
• The fake on the left has a darker blue compared to the more aqua blue for the authentic carton. All the other letterings are a good copy.
Counterfeit Ozempic example
• The fake in left has a different SKU number compared to the original carton.
• The line of the information is misaligned compared to the original, starting from “Refrigerate ..”
Counterfeit Ozempic example
• The fake is missing a white upside down triangle
Counterfeit Ozempic example
• Poor printing image on the fake and missing bold wording “day” and “weekly”. Also missing “Lift here”
• GTIN is incorrect and the order of the various information. The QR code is black and white where in the legitimate carton is blue and white.
Counterfeit Ozempic example
• The fake carton was for a “1 mg” but label has “3 ml” The real does not have “3 ml”.
• The rest is all different below “For single patient use only”
Counterfeit Ozempic example
Attention: Our products have gained world-wide attention mainly due to weight-loss effects.
Counterfeit: This has lead to a surge of counterfeit products.
What?
Novo Nordisk is a Danish pharmaceutical company specialized in diabetes and
obesity.
Who is Novo Nordisk?
Background
Prescription Drugs ONLY
Cold Chain (2-8 °C)
Patient safety: Failure to comply with label or instruction may cause safety concerns
Dangerous: Counterfeit may cause patient harm
Low quality Failure to observe cold-chain or storage requirements may cause patient harm
Why?
Ozempic® is approved for treatment of type 2 diabetes.
It is injected once weekly.
Norditropin® is a growth hormone approved for
treatment of growth disorders.
Rybelsus is approved for treatment of type 2 diabetes.
It is taken as a tablet daily.
Wegovy® is approved for treatment of obesity. It is
injected once weekly.
At-risk Products
How to detect counterfeit products? Keep these 3 things in mind:
Illicit Sales Channels
Quality &
Origin
Contact Novo Nordisk
1. The Sales channel The counterfeits are found on both physical and online channels • Our products should only be sold in
legitimate channels.
2. Quality & Origin The products require professional distribution and cold chain networks. • Our products are only produced by certain
factories
3. Contact Novo Nordisk If you have suspicions that counterfeit products are making it to your market, please contact Novo Nordisk.
WHAT is it about? Sales of semaglutide is increasing online and offline.
• Online sales: E-commerce platforms, social media (influencers and illegal sellers) and fake websites
• Offline sales: Pharmacies, gyms clubs
1. The sales channels
Illicit Sales channels
Sales Sources
HOW to manage it? For online sales: • Be aware on social media (TikTok, X (Ex-Twitter), Facebook…) • The fake advertisements redirect to fraudulent websites • Notify us and will take care of the website shutdown For offline sales: • In any case of suspicious NN product sales, contact us.
Example Ozempic Packaging labelled ”Bayer” found in a gym
Example Ozempic sells online
ORIGIN of the product Our products are only manufactured at the listed sites here
• It is counterfeit if products are claimed manufactured elsewhere
Trends: • Counterfeit Rybelsus from China • Counterfeit Ozempic from Turkey (on the rise)
2. Quality & Origin
Quality &
Origin
Check product quality!
VERIFICATION of packaging • Check the dates • Check the batch number below the dates • If the batch number is in this list, be suspicious • Check the general packaging (Novo Nordisk logo, spelling
errors, quality of openings…)
Example Fake batch number
Example Incorrect packaging (wrong logo and design)
Example Spelling errors on packaging
Suspicion? If you have suspicions that counterfeit products are making it to your market, please contact the people below or directly Global Security
3. Contact Novo Nordisk
Contact Novo Nordisk
We’re available 24/7!
CONTACT PERSONS:
Anne DEVAUD Head Global Product Security (Global) [email protected]
Jim HENDERSON Director Risk Management (US) [email protected]
Benedict CHEN Regional Security Advisor (APAC) [email protected]
Stephen YARDLEY Regional Security Advisor (EMEA) [email protected]
Renata PEREIRA Regional Security Advisor (LATAM) [email protected]
Maria Magdalena Korzycka Global Product Security Coordinator [email protected]
88
Our Production Facilities
Brazil Monte Claros Company: Novo Nordisk Brazil
USA Clayton, Durham, New Hampshire Company: Novo Nordisk Inc. / Novo Nordisk USA (Clayt.)
Japan Koriyama Company: Novo Nordisk Japan
Denmark Bagsværd, Kalundborg, Hillerød, Gentofte, Værløse, Måløv Company: Novo Nordisk Denmark / Novo Nordisk A/S
France Chartres Company: NN France Production
China Tianjin Company: Novo Nordisk China
Our at-risk products are all manufactured from one of these sites. • Any product packaging claiming to be
manufactured elsewhere is counterfeit
If you see a company that doesn’t belong to the one the side, you can’t trust it and you should directly report the shipment
Iran Tehran Company: NN Pars (PSJ)
Algeria Blida, Tizi Ouzou Company: Aldaph SPA
Russia Kaluga Company: Novo Nordisk Russia
All NN products entering ESTONIA come via these importers and at these ports of entry:
Importers and distributors: Producers:
• Novo Nordisk A/S
• NN France Production
• Novo Nordisk Brazil
Distributors:
• Magnum Medical OU
• TAMRO EESTI OU
• BALTFARMA OU
Port of entry: • Magnum Medical LTd.
If you see a company that doesn’t belong to these lists, you can’t trust it and you need to directly report the shipment
Products imported, distributed or with a point of entry elsewhere, are counterfeit or diverted
Main Batch Numbers at risk
Batch Number
If you notice a batch number from this list on a shipment, please be vigilant!
• Batch numbers are written on the back of the packaging, below the dates • They are important numbers for us to track our products and their origin
Currently, we observe the following batch number at risk: Batch do not exist with
NN Product
NS6GG22 Rybelsus®
FT4A281 Ozempic®
NDC7139 Norditropin®
MC74746 Norditropin®
MG5B070 Ozempic®
JS7A925 Ozempic®
NPSG234 Ozempic®
9F808A Norditropin®
Frequently used Batch numbers
Product
MP5B060 Ozempic®
NP5E775 Ozempic®
NS6JT27 Rybelsus®
NO6F617 Wegovy®
• For Ozempic MP5B060, if its 1 mg it is a counterfeit. • For Ozempic NP5E775, batch number does not exist for Ozempic but
exist for Saxenda and sold in Argentina • For Rybelsus NS6JT27, batch number does not exist for Rybelsus but
exist for NovoEight intended to be sold in Colombia
Norditropin® SimpleXx® no more in production worldwide, but still counterfeited
CF Batch numbers: FC83012, NDC7139, MC74746, 9F808A Seen recently in Turkey and Greece Abused by bodybuilders
Counterfeit Rybelsus example • Rybelsus ranks as the second-most
counterfeited Novo Nordisk product • Examine the packaging for spelling
mistakes • The provided images highlight the
spelling discrepancies identified
Genuine Counterfeit
How to differentiate: • Dose Selector extends up to 80
on counterfeit • Label on the pen and carton:
poor quality and not adhering well to the pen
• Counterfeit needles: ALVITA
Modus operandi: • Counterfeiters utilized Apidra SoloStar pens that resemble those of Saxenda. The pens are Sanofi's product, designed for
administering rapid-acting insulin. • They substituted the original Apidra labels with counterfeit Saxenda labels
• They distributed Alvita needles with the pens, in place of Novo Nordisk’s own
Genuine Saxenda® pen
Fake Saxenda pen: • Fake label of poor
quality • Not adhering well
to the pen
Counterfeit Saxenda example
New Modus operandi - NN genuine rapid insulin pen relabeled as Ozempic
Counterfeit
Genuine
Genuine Fiasp® pen
How to differentiate: • Counterfeiters are using
NN rapid insulin pens and relabelling them as Ozempic
• The Ozempic® pen is light blue with a gray injection button, while Fiasp® insulin pens are dark blue with an orange button
Genuine Counterfeit
Counterfeit Ozempic example
How to differentiate: • Dose Selector extends up to 80
on counterfeit • Label on the pen and carton:
poor quality and not adhering well to the pen
• Counterfeit needles: ALVITA
Fake Ozempic pen: • Fake label of poor quality
• Not adhering well to the pen
Modus operandi: • Counterfeiters utilized Apidra SoloStar pens (1) that resemble those of Ozempic (2). The pens are Sanofi's product, designed for
administering rapid-acting insulin. • They substituted the original Apidra labels with counterfeit Ozempic labels (3) • They distributed Alvita needles (4) with the pens, in place of Novo Nordisk’s own
1 2
3 4
• The fake on the left has a darker blue compared to the more aqua blue for the authentic carton. All the other letterings are a good copy.
Counterfeit Ozempic example
• The fake in left has a different SKU number compared to the original carton.
• The line of the information is misaligned compared to the original, starting from “Refrigerate ..”
Counterfeit Ozempic example
• The fake is missing a white upside down triangle
Counterfeit Ozempic example
• Poor printing image on the fake and missing bold wording “day” and “weekly”. Also missing “Lift here”
• GTIN is incorrect and the order of the various information. The QR code is black and white where in the legitimate carton is blue and white.
Counterfeit Ozempic example
• The fake carton was for a “1 mg” but label has “3 ml” The real does not have “3 ml”.
• The rest is all different below “For single patient use only”
Counterfeit Ozempic example